Introduction: We evaluated the use of Tiagabine (Gabitril®), an anticonvulsant, in patients with Primary Fibomyalgia Syndrome (PFS). PFS is a chronic pain condition characterized by a diffuse pain pattern over the entire body. Tiagabine (TGB) increases synaptic gamma-aminobutyric acid (GABA) availability by binding reversibly and saturably to recognition sites associated with GABA transporter protein in neuronal and glial membranes [1] . Methods: Consecutive patients with PFS who were nonresponders to opiates, nonsteroidal antiinflammatory drugs (NSAIDs), tricyclic antidepressants, and gabapentin were enrolled. TGB therapy was initiated at 4 mg qhs as add-on therapy to the patient's current medication regimen. TGB was increased every 3-5 days by 4 mg to 8 mg qhs to a maximum of 12 mg/ day. The following outcome measures were evaluated: McGill Short-Form Pain Questionnaire, numeric pain score, patient and physician subjective global response, examination for degree of tenderness. Patients were followed monthly. Adverse events were noted.
Results: A total of 11 patients (10 women, 1 man) with PFS were given TGB. Mean age was 46 years (range: 31-59). At final outcome measurement, 64% of the patients had received TGB for 12 months (range: 1-12 months) and mean Numeric Pain score decreased from 8.3 (range: 7-10) to 3.7 (range: 0-10) and mean McGill decreased from 38.4 (range: 32-44) to 17.3 (range: 0-30). Patient responses were as follows: excellent = 6 (55%); good = 1 (9 %); fair = 3 (27%); and poor = 1 (9 %). Adverse events were reported by one patient (nausea and sedation). Two patients discontinued treatment; one patient for poor response and one patient due to adverse events. Conclusions: Overall, TGB was well-tolerated and demonstrated an effective response to this verydifficult-to-treat condition. The eleven cases reflect a need for further investigation of TGB in the form of double-blind placebo-controlled studies.
The Lidoderm patch, which consists of 5% topical lidocaine, is FDA approved for and has been used with success in patients with neuropathic pain associated with postherpetic neuralgia. The patch is formulated to deliver lidocaine to the peripheral sites of application with minimal systemic levels, making it ideal for localized pain, while reducing risk of systemic adverse events or drug-drug interactions. Randomized controlled clinical trials have shown that patients with postherpetic neuralgia report a significant decrease in pain intensity and allodynia when using the lidocaine patch.
Because of its demonstrated efficacy with intense postherpetic neuralgia pain, we have used it for multiple musculoskeletal and neurological conditions as symptomatic treatment for localized pain relief. In our practice, we have found the patch to be useful for back and neck pain, tendonitis and bursitis, as well as entrapment neuropathies, such as carpal tunnel syndrome, cubital tunnel syndrome, and meralgia paresthetica. As the patch can be cut to any size, it is remarkably versatile and may be applied to virtually any area of the body, provided the skin is intact.
We conducted a retrospective, single-center study of 14 patients with pain secondary to entrapment neuropathy, tendonitis, or bursitis. Of the 14 patients, 12 were female, and the average age was 46 with ages ranging from 25 to 81 years. Eighty-two percent of patients reported significant improvement over baseline symptoms, the average improvement being 44%. Even those patients who were previously on opioid analgesics such as Oxycodone and Propoxyphene reported a significant improvement in their symptoms after the addition of the Lidoderm patch, 65% on average. These results suggest that Lidoderm is an effective treatment of the pain associated with entrapment neuropathies, tendonitis, and bursitis. It potentially decreases the need for oral medications and injections. Further studies are warranted.
surgeries and one following extensive facial reconstruction secondary to basal cell carcinoma. All patients responded with short-term pain relief to blocks of the respective peripheral branches of the trigeminal nerve (supraorbital and infraorbital nerve blocks). However, they failed other interventions including conservative medical management, acupuncture, and radiofrequency ablation. All patients had successful extended peripheral nerve stimulation trials and subsequently underwent permanent implantation with percutaneous leads placed in proximity of the supraorbital or infraorbital nerve. Follow-up over 2 months after implantation revealed significant decreases in visual analog scale pain scores and drastic improvement in functional capacity in all three patients. In this report, we describe the technique and its advantages. Introduction: The Implantable Systems Performance Registry (ISPR) is an ongoing, prospective, multicenter postmarket surveillance registry developed as a followup to a fax-based registry, the National Outcomes Registry for Low Back Pain [1, 2] . ISPR is designed to monitor U.S. Medtronic infusion and neurostimulation systems. The objectives of ISPR include ongoing product evaluation with the goal of improving quality and reliability; longitudinal analyses evaluating implant and practice techniques; and patient and device outcomes tracking. The publication and reporting strategy for ISPR is overseen by a multispecialty advisory board. Methods: ISPR centers follow standard clinical practice and a common registry protocol. ISPR collects registry data through a secure Web-based system, which enables electronic data capture (EDC) from each center. Information registered with the FDA-required Device Registration System (DRS) is automatically loaded into ISPR and electronic action items are generated. These alerts prompt the center to submit electronic data under various categories including enrolling a patient, enrolling a device, and providing a patient status update at 6-month intervals. The center reports events such as those requiring surgical intervention, patient death, and lost to follow-up. FDA-required Medical Device Reporting (MDR) is completed through an automatic notification process for qualifying events. The prepopulation of ISPR with previously entered information and automatic notification processes are key design advantages. Results: Within the first 8 months of operation, ten centers actively contributed data for 509 enrolled patients with implantable systems. The intent of this presentation is to describe the methodology and present preliminary results.
Conclusions: This prospective clinical registry collects comprehensive information and long-term outcomes related to system performance. We will utilize data to improve products and guide development toward the goal of better patient outcomes. This registry will serve as a foundation and electronic platform for future outcome registry projects.
tigated the effect of BoNT-A on chronic, refractory low back pain (crLBP) of 75 adults. The cohort's mean age was 46 years (range 19-72). The patients received BoNT-A (100 u/CC) into paraspinal muscles at baseline and when the pain recurred, usually at 4, 8, and 12 months. BoNT-A was administered into three to five paraspinal levels on each side (50 units/site), as close as possible to the tender points. The total dose per session varied from 200 to 450 units (mean 285) depending on the pain extension and laterality. The pain characteristics and patient's functional limitations were recorded via visual analog scale (VAS), Oswestory Low Back Pain Questionnaire (OPQ) and Pain Impact Questionnaire (PIQ), at baseline, 3 weeks, 2, 4, 6, 8, 10, 12, and 14 months. They also had a neurological examination and recorded inquiry of side effects at these intervals.
Patients did not change their physical therapy program or pain medications during the period of the study. A significant response to pain and significant functional improvement were noted in 56 and 54% of the patients at 3 weeks and 2 months after first treatment (P < 0.05 Introduction: A noninvasive, preprogrammed, credit card-sized, iontophoretic, fentanyl HCl patientcontrolled transdermal system (PCTS) is in development for the treatment of acute postoperative pain. In this setting, administration of morphine via intravenous patient-controlled analgesia (IV PCA) devices is common. A large (N = 636), randomized, multicenter study, which included a variety of surgery types, found the two approaches to be therapeutically equivalent. This subanalysis of that study compared their safety and efficacy in the subset of patients who had undergone general surgery. Methods: Adult patients were titrated to comfort with opioids after major surgery and randomized 1 : 1 to the fentanyl PCTS or IV PCA morphine. The subset of general surgery patients contained 53 patients in the PCTS group and 58 patients in the morphine IV PCA group. The fentanyl PCTS delivered 40 mg fentanyl, up to 6 doses/hour. IV PCA delivered 1 mg morphine, up to 10 mg/hour. Pain intensity scores, measured by the visual analog scale (VAS), were recorded before randomization and thereafter for 72 hours. The primary efficacy end point was the proportion of patients rating their method of pain control as excellent or good (versus fair or poor) during the first 24 hours (patient global assessment, PGA). Results: PGA was comparable between groups, with 44/53 (83.0%) patients receiving the fentanyl PCTS rating their pain control method as excellent or good, compared with 46/58 (79.3%) receiving morphine IV PCA (difference = 3.7%; 95% CI, -10.8%, 18.2%; P = 0.618). Pain intensity scores at 24 hours were 21.5 for PCTS and 21.6 for IV PCA (P = 0.994); betweengroup scores were similar at all measured time points. The most frequent treatment-related adverse events in both groups were nausea, pruritus, and vomiting. Conclusions: In patients who had undergone general surgery, the fentanyl HCl PCTS was comparable in efficacy to a standard regimen of morphine IV PCA for postoperative pain control. [1] [2] [3] . Pretreatment questionnaire results were significant for major depression in 53% (N = 8) of patients with a CES-D ≥ 27. After completing rehabilitation, paired t-tests revealed significant decreases in pain severity/suffering (P < 0.05), depression (P < 0.05), catastrophizing (P < 0.01), and improved physical functioning (P < 0.05). This patient population, which has not often been described in the medical literature, has a significant level of depression and debilitation warranting future research. Furthermore, these findings suggest that patients with severe, chronic knee pain can significantly improve physical and emotional functioning in a pain rehabilitation program that incorporates multimodality therapies. Introduction: Pain management in the hospital setting is a high-volume, high-risk and problem-prone area that cuts across several areas of patient care, including patient rights, assessment, education, provision of care, and staff education. Despite the significant strides made in improving pain control in the past few decades, the undertreatment of pain remains a significant national and international problem. Following the implementation of a pain management performance improvement plan how much does the attitude and opinion of nurses and physicians on common pain management myths change? Materials and Methods: To measure changes in the attitude and practice pattern of the providers, items were adapted from previously published studies addressing similar issues. Randomly selected charts were reviewed monthly to monitor progress in documentation. After obtaining baseline data, an interdisciplinary team was formed and a multiprong approach to improving hospital-wide pain management was implemented. Facets included staff and patient education, screening of pain as fifth vital sign, regular chart review, inclusion of information on pain in new employee orientation, training pain resource providers, organizing informational pain fair, and organizing regular town hall discussions with hospital staffs on pain topics by pain specialist. Results: The questionnaire was administered to about 50 randomly selected providers in 1999 and repeated annually. The results showed that the proportion who believed that addiction to pain medication was uncommon rose from 50% in 1999 to 68% in 2003. The appropriate attitude of encouraging patients to talk about their pain continues to be maintained at a high level (76% in 1999 to 89% in 2003). Conclusion: The data suggest that hospital-wide pain improvement programs when carried out using a multidisciplinary, multifaceted approach can lead to improved pain conceptions among hospital providers and this can be sustained over time.
Background: The tiered treatment of cervical radicular pain, due to a focal protrusion, which has failed to improve with noninvasive rehabilitation measures, frequently incorporates an epidural/selective nerve root injection. Some have investigated the use of percutaneous discectomy as an additional option to avoid an open surgical procedure. The reported results of glucocorticoid injection have been mixed, ranging from 50% to 75% success. There are only limited published reports of percutaneous discectomy. All of them have used laser technology, and the methodology of these publications obviate the formulation of any judgment concerning their success. Purpose: To report the effectiveness and side effects following percutaneous disc decompression using coblation technology combined with a selective nerve root injection (SNRI) to treat cervical radiculopathy. Methods: Consecutive patients were prospectively enrolled. Inclusion criteria were arm greater than neck pain; corroborative focal protrusion on magnetic resonance image (MRI); a minimum of a corroborative myotomal deficit, positive electrodiagnostic study or positive diagnostic root block; failure of oral antiinflammatory medication, physical therapy and/or imminent surgery. Patients were excluded with a focal protrusion over 5 mm. Side effects were assessed at six predetermined postoperative intervals through 2 weeks. Outcomes were assessed using a visual analog scale (VAS) preoperatively and at 2 weeks, 1, 2, 3, and 6 months postoperatively. Each subject was reviewed by a spine surgeon to determine if they were a potential operable candidate. Data collection was performed by an independent reviewer. Statistical analyses were accomplished using McNemar's and the Wilcoxon signed rank test. Results: Each of the 21 patients, ranging in age from 28 to 54, with an average symptom duration of 36 weeks, was considered a potential surgical candidate by a fellowship trained spine surgeon. Mean preoperative VAS was 6.9 (range 4-9). Mean serial follow-up interval VAS rating was: 2.9 (range 0-7.7; 3 with no pain) in 21 patients at 2 weeks; 2.1 (range 0-6.7; 11 with no pain) in 21 patients at 4 weeks; 1.7 (range 0-6.8: 12 with no pain) in 21 patients at 8 weeks; 1.2 (range 0-6; 8 with no pain) in 21 patients at 3 months; and 1.3 (range 0-8; 7 with no pain; 5 with VAS of 1; 3 with VAS of 2) in 19 patients at 6 months. There was a statistically significant reduction in the VAS rating at each followup (P < 0.0001). As well, there were clinically significant reductions in the VAS rating; mean percentage reduction of 58, 70, 75, 83, and 81 at the respective serial follow-ups for the entire population (failures and successes). There were no significant early term side effects. One patient underwent successful surgery between 8 and 12 weeks post procedure. One patient underwent repeat disc decompression and snri between 3 and 6 months post procedure. [3] , and the Coping Strategies Questionnaire catastrophizing subscale (CSQ-C) [4] . A two-way repeated measures of analysis of variance was conducted to compare men and women with FM at the time of admission and dismissal. Additionally, the difference in mean admission and dismissal scores was analyzed using paired t-tests (two-tailed).
Results: The mean (SD) age and duration of illness for men was 45 years (12) and 11.8 years (13.5) while the mean (SD) age and duration of illness for women was 46 years (13) and 9.8 years (9.0), respectively. No statistically significant (P > 0.05) gender effect was identified. However, the difference in mean admission and dismissal scores from six subscales of the MPI and SF-36 demonstrated significant improvement (P < 0.001).
Similarly, scores from the CES-D and CSQ-C also showed significant improvement (P < 0.001). In general, pain severity, depression, and catastrophizing declined while perceived control, health perception, and physical/social functioning improved. Introduction: The ongoing obesity epidemic has created formidable challenges for physicians engaged in the postoperative care of these patients. Postoperative pain management of the obese may be challenged by considerations of altered airway management, cardiopulmonary physiology, drug dosing calculations, and negative associations by healthcare workers toward these patients [1] . We compared the satisfaction of postoperative pain management of obese and nonobese patients. Methods: Twenty patients with a body mass index (BMI) greater than 27 (25% greater than ideal weight) and 20 patients with BMI less than 27 were treated in the Post-Anesthesia Care Unit (PACU) after joint replacement surgery utilizing a pain management protocol whereby morphine sulfate was administered based on body weight and numerical rating scale. Data concerning patient satisfaction with pain management, milligrams of morphine administered, and pain scores were collected. Results: Seventy-five percent of patients with a BMI less than 27 were satisfied with their pain management in the PACU, while only 25% of patients with a BMI greater than 27 were satisfied. Eighty percent of patients with BMI greater than 27 received less total morphine sulfate, and reported numeric pain scores significantly higher than patients with BMI less than 27. Conclusion: Obese patients may be at significant risk for undertreatment of acute postoperative pain. This may reflect unwarranted bias against this patient population [2] . Results: Duloxetine 60 mg QD and 60 mg BID demonstrated significant improvement in the treatment of DNP and showed rapid onset of action, with separation from placebo occurring at week 1 on the 24-hour average pain severity score. For all secondary measures for pain (except allodynia), mean changes showed superiority of duloxetine over placebo, with no significant difference between 60 mg QD and 60 mg BID. Reduction in 24-hour average pain severity was caused by direct treatment effect. CGI and PGI evaluation also demonstrated greater improvement on duloxetine-versus placebo-treated patients. Duloxetine showed no notable interference on diabetic control, and both doses were safely administered and well tolerated. Conclusion: This study confirms previous findings that duloxetine at 60 mg QD and 60 mg BID is safe and effective in treating DNP.
Introduction: Duloxetine is a balanced and potent reuptake inhibitor of both serotonin (5-HT) and norepinephrine (NE). As 5-HT and NE inhibit pain via descending spinal cord pathways, duloxetine's dual reuptake inhibition activity may make it an effective agent for the treatment of diabetic neuropathic pain. Study Design: In a 28-week, multicenter, open-label study, 449 patients diagnosed with diabetic neuropathic pain (DN) were randomized 3 : 1 to either duloxetine 60 mg BID or duloxetine 120 mg QD treatment groups. The primary study objective was to assess duloxetine's tolerability and safety in DN patients. Standard clinical tests, labs, and electrocardiograms were performed for all patients. Secondary efficacy measures included the Brief Pain Inventory (BPI) and Clinical Global Impression of Severity (CGI-S) scales.
Results: Protocol completion rates were 63.8% and 62.6% for the duloxetine 60 mg BID (N = 213) and duloxetine 120 mg QD (N = 72) patient groups, respectively. Both treatment groups showed improvement from baseline to end point on all subscales of the BPI and the CGI-S (P < 0.005). Adverse events were the most frequent cause of discontinuation for both treatment groups. Statistically significant but clinically unremarkable changes occurred in some cardiovascular parameters from baseline to end point. In both duloxetine treatment groups, heart rate increased slightly (P < 0.05) and systolic blood pressure (BP) was unaffected while diastolic BP decreased slightly in duloxetine 120 mg QD patients (P < 0.05). A sustained (three consecutive visits) BP elevation was reported for 18 (5.5%) and 6 (5.4%) of patients receiving duloxetine 60 mg BID and duloxetine 120 mg QD, respectively. Conclusions: For patients with DN, duloxetine is tolerable as demonstrated by its high percentage of patients completing the study, can be safely administered, and was efficacious in improving the painful symptoms associated with diabetic neuropathy. Aim: Abuse and diversion of controlled-release (CR) oxycodone is of great concern to health officials. Abusers can easily extract the full dose of oxycodone from CR preparations, resulting in an immediate, large spike in oxycodone blood levels and a powerful morphine-like high. Recreational use of oxycodone can lead to respiratory depression, death, or opiate addiction. In the U.S., oxycodone abuse resulted in over 20,000 emergency room visits and hundreds of deaths in 2002. Remoxy is a novel oxycodone formulation designed to deter abuse. Remoxy's gel-cap formulation provides a long-acting dose of oxycodone, yet cannot be abused by crushing, freezing, heating, or dissolving in water, alcohol, or other common beverages. The pharmacokinetics of Remoxy versus commercially available CR oxycodone are compared after swallowing whole and following abuse by crushing. Methods: Remoxy 10 mg and a commercially available sustained-release oxycodone 10 mg were first swallowed whole by healthy male volunteers. In tests designed to mimic common methods of abuse, each drug was crushed and stirred in water or alcohol before ingestion. After each dosing, plasma oxycodone levels were monitored for 48 hours and also compared with those produced by an immediate-release (IR) commercial oxycodone formulation. Results: Remoxy and the commercial CR formulation produced similar plasma oxycodone levels when each was swallowed whole. After crushing and ingesting with water or alcohol, the commercial CR formulation resulted in even higher oxycodone plasma concentrations than those produced by the IR oxycodone tablet. In contrast, oxycodone plasma concentrations after crushing Remoxy were markedly lower at early time points compared with both the commercial IR and crushed CR formulations and only slightly above levels produced by swallowing Remoxy whole.
Conclusions Compared with controls at the 23-year follow-up, the patient cohort experienced increased painful symptoms (2.99 vs 2.14 as measured by Patient Health Questionnaire-PHQ) and overall disability from pain (30.16 v. 18.12-Graded Chronic Pain Scale) after covariate adjustment (both P < 0.001). Compared with controls, patients who experienced pain were more likely to have current MDD as measured by the PHQ (15.9% vs 6.3%, P < 0.013). Among participants with pain (controlling for sociodemographics and medical conditions), the depressed patient cohort reported more medications used (3.59 vs 1.81, P < 0.001) and days cut down on usual activities (5.38 vs 3.39; P < 0.015). In the absence of pain, patients differed from controls only on the number of medications ever used (2.38 vs 0.933, P < 0.001).
This study illustrates how depression and pain measured 23 years after initiating depression treatment affects their long-term functional and workplace outcomes relative to a matched community control cohort. Pain was more prevalent 23 years post index in the depressed patient cohort compared with the community control cohort. Among individuals with pain, depressed patients showed poorer functioning and used more medications than did controls. Among individuals without pain, depressed patients differed from controls only in that they used more medications. At 23 years after the index depression treatment, patients with current pain have more severe depression than did patients without pain. 3 ). There were no significant differences in the relative improvements between groups in either the VAS (P = 0.46) or the OWS (P = 0.35). Within the PRF group, comparisons of the relative change at 3 months for both VAS (P = 0.21) and OSW scores (P = 0.61) were not significant. However, within the RF group, the VAS (P = 0.02) and OSW scores (P = 0.03) improved significantly at 3 months. Discussion: This study suggests that there was no significant difference in long-term outcome in the treatment of lumbar facet syndrome between the RF and PRF groups. However, in patients who received RF there was significant improvement in both VAS and OSW at 3 months post treatment, findings not seen with PRF. Introduction: Spinal cord stimulation (SCS) therapy has been shown to be an effective modality to control pain [1] . In addition to anesthesiologists, specialists in neurosurgery, neurology, orthopedic surgery, and physical medicine and rehabilitation utilize SCS as part of the treatment regimen for chronic pain. Failures with this treatment have been attributed to implant technique, physiologic adaptation, changing disease state, increased activity level, and hardware or mechanical failures. However, patient selection criteria, particularly psychosocial factors, were recently identified as the primary reason to explain the inability of patients to achieve sustained long-term pain relief with SCS therapy [2] . As part of a national survey, we asked physicians from different specialties to identify patient selection criteria felt important to predict success with SCS therapy. Methods: A 38-question survey was mailed to 1,000 SCS implanters across the United States in April 2003. Physician specialists surveyed represented anesthesiology, neurosurgery, neurology, orthopedic surgery, and physical medicine and rehabilitation. Practitioners were asked to identify important criteria used in the patient selection process for SCS therapy. Areas surveyed were: 1) priority of criteria used for patient selection; 2) percentage of patients who require psychological evaluation prior to trial; and 3) elements of a psychological evaluation that eliminate a patient as a candidate for a trial. Physician responses were compared by specialty to determine practice pattern variances. Statistical significance between specialties regarding categorical and ordinal outcomes was assessed using chi-square tests of association or Fishers exact test. Wilcoxon rank-sum tests were used for percentage outcomes.
Results: A total of 165 surveys were completed and analyzed. As 91% of the respondents were anesthesiologists or neurosurgeons, only these two groups were included for comparative analysis. Compared with anesthesiologists, neurosurgeons considered a clear etiology of pain to be a very important factor in the selection of appropriate candidates for SCS therapy (P < 0.05). However, anesthesiologists identified patients with a current substance abuse history as very poor candidates for success of this therapy more often than neurosurgeons (P < 0.005). Physicians from both specialties required psychological evaluation of patients prior to SCS trial in 75-100% of cases (P = 0.2). Borderline personality and bipolar disorder were identified by anesthesiologists more commonly as exclusion criteria for SCS trial (P < 0.05). Conclusions: SCS therapy is an integral part of the management of chronic pain states utilized by physicians of different specialties. This survey highlights significant differences in selection criteria used by anesthesiologists and neurosurgeons to identify candidates likely to be successful with this mode of therapy. These data should serve as an impetus for the development of well-controlled prospective studies to assess if these differences in practice patterns affect patient outcomes. Summary: Significant differences exist between anesthesiologists and neurosurgeons in the selection criteria used for SCS therapy, including the identification of a clear etiology of the painful condition, presence of active substance abuse, and diagnoses of borderline personality or bipolar disorder.
Introduction: This study investigates the impact of comorbid depression on functional status and pain outcomes in chronic low back pain (CLBP) patients treated with transdermal fentanyl. Methods: Data come from an observational study conducted at 17 clinical centers in the U.S. eligible patients (N = 131) who had CLBP for >3 months and were receiving short-acting opioids when transdermal fentanyl was added. Patients completed the Treatment Outcomes in Pain Survey (TOPS), the SF-36 Health Survey, the Oswestry Disability Index (ODI), and a 10-point numerical rating scale (NRS) of pain severity at baseline and after >9 weeks of transdermal fentanyl treatment. Comorbid depression was defined as a score <42 on the SF-36 mental health scale at baseline and final visits. Nondepressed patients scored >42 on the SF-36 mental health scale at baseline and final visits. Changes in TOPS, SF-36, ODI and NRS scores from baseline to final visits were compared between depressed and nondepressed CLBP patients using Student's t-tests.
Results: Nearly one-half of CLBP patients had comorbid depression (N = 62). Nondepressed CLBP patients showed significantly larger improvement than depressed CLBP patients in SF-36 physical functioning (5.4 vs 1.6 points, P < 0.01), role physical (5.2 vs 2.1 points, P < 0.05), and physical summary (6.3 vs 2.5 points, P < 0.05) scales, the TOPS lower body functioning (11.3 vs -4.9 points, P < 0.05) and total pain experience (-9.8 vs -5.9 points, P < 0.05) scales, the ODI (-11.9 vs -3.5 points, P < 0.01), and the NRS (-1.9 vs -1.1 points, P < 0.05). Changes in other SF-36 and TOPS scales were generally greater among nondepressed CLBP patients, although the differences were not statistically significant. Conclusion: Although depressed CLBP patients realized HRQoL improvements with transdermal fentanyl, this improvement was generally more favorable in nondepressed patients. Effective management of pain and HRQoL outcomes in CLBP patients requires an assessment of comorbid depression.
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Introduction: Femoral nerve block (FNB) is commonly used to alleviate pain after total knee replacement (TKR). Although the efficacy of this block is established, the effects of preoperative versus postoperative FNB have not been studied. The aim of this study was to compare the effects of preoperative versus postoperative FNB in patients undergoing TKR.
Material and Methods: Thirty patients were enrolled in the study. Patients were randomly assigned into two groups with both groups receiving general anesthesia. Group A received FNB preoperatively and group B received FNB postoperatively. FNB consisted of a single injection technique of 30-40 mL of ropivicaine 0.5% with epinephrine. A nerve stimulator was used nerve identification. Pain scores were assessed with a visual analog pain scale (VAS) at hourly intervals in the recovery room (RR), the morning after surgery and at the completion of the study. Narcotic requirements in the operating room, RR, and ward were collected for each patient. Results: Twenty-nine patients completed the study. Group A had 14 patients and group B had 15 patients. The two groups were similar with respect to age and sex (P > 0.05 NS). No differences were observed between groups in pain scores collected in the RR (P = 0.71 NS) or the morning after surgery (P = 0.44 NS). Group B had lower pain scores at the completion of the study (P = 0.01). Intraoperative and RR narcotic administration was similar between groups (P = 0.48 NS and P = 0.86 NS, respectively). No differences were observed between the groups in postoperative narcotic utilization (P = 0.158 NS). Conclusion: The decision to perform FNB preoperatively or postoperatively is driven by several factors, including time considerations, patient preference, and reimbursement issues. This study found little evidence that the timing of the procedure conferred any particular benefit to either patient group.
Introduction and Study Aim: Multiple epidemiologic surveys have documented the high prevalence of pain in cancer patients. Many cancer patients would consider suicide if their pain was not well controlled. One of the problems inherent in assessing and managing pain is the absence of objective outcome measures for pain. The numeric pain scale and patient satisfaction are often used as pain outcome measures. The aim of this study was to determine if cancer patients who report less pain on the numeric rating scale have higher satisfaction compared with those with higher pain levels. Materials, Method, and Results: We surveyed 56 oncology patients in the outpatient (39) and inpatient (17) settings, using an adaptation of the American Pain Society quality improvement pain questionnaire. Current pain scores ranged from 0 to 10 with a median score of 3. Sixty-three percent had mild pain (0-3). Sixteen percent had moderate pain (4-6), while 21% reported severe pain (7-10). Forty-seven percent of the patients surveyed reported that they were very satisfied with the way the physicians had managed their pain care, 47% were satisfied, while 5% were dissatisfied. Using chi-square analysis, there was no statistically significant relationship between the average pain score (in the last 30 days) and level of satisfaction or the degree of pain relief obtained with treatment and level of satisfaction at P = 0.1 or less. Conclusion: Our results suggest that although level of patient satisfaction is commonly used as an outcome measure of pain care, there was no statistically significant relationship between the average pain level or degree of relief obtained from pain treatment and degree of patient satisfaction. This needs to be confirmed with larger studies. Clinicians and researchers should understand that there are several nonpainrelated factors that influence the level of satisfaction of patients with their pain care.
pain syndromes. As the popularity of this medication has increased, so have reports of drug diversion and OxyContin-associated deaths. This study was conducted so to provide quantitative information concerning compliance with OxyContin prescriptions in chronic pain patients. Data were also collected for other common opioids and illegal drugs (not discussed here). Materials and Methods: Random, urine samples were collected from 14,712 patients prescribed opioids for chronic pain syndromes by the staff of 127 outpatient pain clinics. Urine samples were analyzed by two, quantitative, commercial Methods: 1) Abbott FPIA; and 2) GCMS using commercial protocols available from UD Testing, Inc., Marco Island, FL. These protocols adjust raw urine drug concentrations so to compensate for urine dilution, urine pH, body weight, and renal function. Data were collected for commonly prescribed opioids (oxycodone/oxymorphone, hydrocodone/ hydromorphone, codeine/morphine, 6MAM), benzodiazepines, and drugs of abuse by a certified, independent laboratory. Results: Evaluation of the urine demonstrated that, of urines collected from patients prescribed OxyContin and analyzed by GCMS and FPIA: 1) 20.1% were negative for opioids; 2) 53.6% failed to be within expected ranges for urine concentration-dose curves; and 3) 33.5% were within expected ranges for urine concentration-dose curves. Also, 13.7% of patients prescribed medications other than OxyContin or oxycodone IR were positive for oxycodone by GCMS and FPIA. Oxycodone dose-urine concentration curves were generated using data from compliant patients (normalized to standard conditions) for both FPIA and GCMS: (*) FPIA = 40.6*(total daily dose)* Introduction: Opioid-related adverse events (AEs) can limit tolerability in opioid-naive patients. Cautious titration from a low dose may improve tolerability. This study evaluated the tolerability of oxymorphone extended-release (ER) in opioid-naive patients experiencing chronic, moderate-to-severe low back pain (LBP) by carefully titrating from a low starting dose (5 mg) to an effective stable dose. Materials and Methods: An open-label study was performed in outpatients 18 years of age or older with a baseline pain intensity score of 40 or more on a 100-mm visual analog scale and a pain rating of moderate or severe on a categorical scale. Patients received oxymorphone ER 5 mg q12h for 2 days and were then titrated for 31 days or less to an effective stable daily dose. The primary outcome assessment was the tolerability of oxymorphone ER during dose titration. Results: Forty-eight patients with LBP were enrolled. The mean average pain at baseline was 6.3 on a 0-10 scale of increasing pain. Thirty-nine patients (81.3%) were successfully titrated to an effective stable dose that reduced pain to less than or equal to 4/10 for 3 of 5 consecutive days; most stabilized patients (28/39, 72%) were titrated within 14 days. Six (12.5%) patients discontinued because of AEs and one (2%) each for protocol violation, withdrawing consent, or failure to meet titration criteria. Mean daily dose of oxymorphone ER was 32.7 mg (range, 10-100 mg). The most common AEs were those typically associated with opioid treatment, including constipation (37.5%), somnolence (25%), and nausea (25%); however, the rate of vomiting was low (6.3%). Conclusions: Oxymorphone ER was well tolerated by most opioid-naive patients with chronic, moderate-tosevere LBP when therapy was initiated at a low dose (5 mg q12h), followed by titration to a stable dose that provided effective pain relief.
Background: Duloxetine has been shown to be safe and effective in the management of diabetic peripheral neuropathic pain (DPNP). Diabetic patients are predisposed to hypertension and other chronic medical conditions. Here we assess safety and tolerability data for duloxetine in patients with DPNP who also had comorbid conditions at study entry. Methods: Data were pooled from two double-blind, placebo-controlled studies in which patients (age ≥ 18 years) with a diagnosis of DPNP were randomized to receive duloxetine (20 mg QD, 60 mg QD, or 60 mg BID; N = 568), or placebo (N = 223) for 12-13 weeks. Safety assessments included discontinuation rates, spontaneously reported treatment-emergent adverse events, and changes in vital signs. Results: At study entry, mean age across all patients was 60.4 years (SD = 10.8), mean duration of diabetes was 10.8 years (SD = 9.6), and mean duration of diabetic neuropathy was 3.8 years (SD = 4.1). The most commonly utilized concomitant medications included analgesics (aspirin, acetaminophen), oral antidiabetics (metformin, glibenclamide, glipizide), cholesterollowering agents (atorvastatin, simvastatin), and antihypertensives (lisinopril, atenolol). The most common comorbid conditions among all patients at baseline (other than diabetes mellitus) were hypertension, hyperlipidemia/hypercholesterolemia, gastroesophageal reflux disease, and erectile dysfunction. The rate of discontinuation because of adverse events in duloxetine-treated patients with baseline hypertensive disorders was similar to that in patients without hypertensive disorders (13.5% vs 14.5%, respectively). The incidence of treatment-emergent adverse events in patients with baseline comorbid conditions was similar to that observed in patients who did not have the condition at baseline. Mean baseline-to-end point changes in sitting systolic and diastolic blood pressure (BP) in patients with baseline elevated BP did not differ significantly from those observed in patients without elevated BP at baseline (e.g., for sitting systolic BP, elevated: duloxetine -9.3 mm Hg vs placebo -8.4 mm Hg, P = 0.639; normal: duloxetine 3.6 mm Hg vs placebo 2.0 mm Hg, P = 0.255). Conclusions: In this study, the safety and tolerability of duloxetine in the management of DPNP were not significantly affected by the presence of baseline comorbid conditions Aim: Oxytrex(tm), a novel drug candidate for moderateto-severe pain, combines oxycodone and ultra-low-dose naltrexone, an opioid antagonist. A clinical trial in osteoarthritis showed significantly greater pain relief from Oxytrex than from oxycodone. Ultra-low-dose opioid antagonists have also been shown to alleviate opioid tolerance and dependence in rodents. The present work assessed the potential for abuse and addiction of Oxytrex versus oxycodone in rat models of drug reward, drug-taking, and drug-seeking. Methods: The acute rewarding or "euphoric" effects of Oxytrex versus oxycodone were assessed in the conditioned place preference paradigm. Time spent in an environment previously paired with Oxytrex or with oxycodone indicated the rewarding potency of each. Next, the abuse potential of each drug was assessed by measuring active drug-taking and subsequent drugseeking displayed during abstinence. Rats pressed a lever for IV infusions of oxycodone or Oxytrex under a schedule of increasing lever-pressing requirements. After three extinction sessions in which drug was unavailable, lever-pressing was measured again after rats received a "free" injection of oxycodone or were sub-mitted to foot-shock stress, mimicking triggers of relapse in human addicts.
Results: Rats showed a conditioned place preference to oxycodone but not to Oxytrex, suggesting a lack of rewarding effect of an analgesic dose of Oxytrex. In the self-administration experiment, rats self-administering Oxytrex took more infusions than rats self-administering oxycodone, suggesting a lower rewarding potency of Oxytrex compared with oxycodone. Rats selfadministering Oxytex also showed significantly reduced drug-seeking precipitated by the triggers of relapse. in both childhood and adulthood. The majority of women (50%) and men (61%) reported abuse in childhood and adulthood (53% and 59%). Women reported higher molestation (P = 0.06) and lower physical abuse scores (P = 0.01) in childhood than men, and higher penetration (P = 0.02) in adulthood. In conclusion, our study supports previous findings that men have higher rates of childhood physical abuse. We also found a high prevalence of both rape (18%) and molestation (20%) in childhood among men with CP. These results stress that questions regarding abuse need to be routinely asked to both men and women with CP. Further research is needed to investigate the long-term repercussions of an abuse history in this understudied population.
Objective: To compare the prevalence, comorbidities, and utilization of an "opioid abuse" cohort of managed care patients with matched controls. In this study we looked at 30 claimants with low back pain who were getting Workers' Compensation benefits and had been off work for at least 1 year. We compared these with 30 outpatients who had psychological problems and who were being treated with psychotropics. In order to assess for possible psychopathology the Personality Assessment Inventory (PAI) was used. The PAI is a self-used objective inventory of adult personality designed to provide information on clinical variables. It contains 344 items, which comprise 22 nonoverlapping clinical scales, 4 validity scales, 11 clinical scales, 5 treatment scales, and 2 interpersonal scales.
We found that 81% of the Workers' Compensation claimants had problems suggestive of major depressive disorder compared with 46% of outpatients. For somatization disorder it was 68% compared with 36%. For borderline personality disorder it was 54% compared with 23%. Generalized anxiety disorder was found in 45% of claimants and 23% of outpatients. Posttraumatic stress disorder 50% claimants, 20% outpatients. Polysubstance abuse was equal in prevalence. Symptoms suggestive of schizophrenia were found in 27% of disabled workers and 6% of outpatients. Somatoform pain disorder was in 18% of claimants and 6% of outpatients. All of these results were statistically significant. The PAI is suggested as a useful test for evaluation of psychological problems in Workers' Compensation claimants.
Objective: Primary care practitioners (PCPs) care for most patients with chronic pain but are reluctant to prescribe opioids, fearing diversion, abuse, addiction, and regulatory scrutiny. Cost-effective strategies are needed to support PCPs' pain management. We describe the results of a Nurse Practitioner (NP) and Pharm.D intervention, the Opioid Renewal Clinic (ORC), which supported PCP pain management in a high addiction risk population within an academic urban tertiary care VA hospital. Methods: The program developed in three stages. 1) Information-gathering and design. Over 6 months, focus groups with PCPs identified needs for an effective program. 2) Program initiation providing: opioid treatment agreements (OTAs), random urine screens (RUDSs) (specific for individual opioids and other regulated meds), frequent visits, telephone contacts, patient education materials, DEA and state-specific guidelines for opioid prescribing, and consultation. All data were recorded electronically in the VA medical record. 3) Maintenance and evaluation. The program was monitored over 21 months by regular team meetings to review patients and protocols. We evaluated patient adherence, PCP rates of use of opioid treatment agreements and urine drug testing, and PCP satisfaction by questionnaire. Results: A total of 335 patients were referred to ORC. Of 170 (50.7%) with documented aberrant behaviors, 58 (33%) adhered to the OTA, 54 (32%) self-discharged, 22 (13%) were referred for addiction treatment, 6 (4%) with consistently negative RUDSs were weaned from opioids, and 30 (18%) new patients continued monitoring. The 165 (49.3%) referred for complexity, including history of substance abuse or need for A survey conducted to evaluate the prevalence and characteristics of breakthrough pain (BTP) in patients with chronic noncancer pain identified 48 patients (63% women, 38% men) with primary neuropathic pain diagnoses and controlled baseline pain (T moderate intensity). Pain diagnoses included: neuropathy (other) in 44%, complex regional pain syndrome in 35%, peripheral neuropathy in 10%, postherpetic neuralgia in 4%, diabetic neuropathy in 2%, and central pain in 2%. Pain had been present for a median of 6 years (range 1 month to 55 years). Medications being used included: any opioid in 94%, sustained-release opioids in 67%, methadone in 15%, short acting opioids in 79%, nonsteroidal anti-inflammatory agents in 31%, antidepressants in 58%, and anticonvulsants in 56%. Each patient's pain was characterized by a phone interview using a BTP pain assessment algorithm originally designed for cancer patients [1] . Seventy-nine percent of these patients (38/48) reported temporary flares of severe or excruciating pain (i.e., BTP). Forty-five different types of BTP were described by 38 patients. The median number of episodes per day was 1.5 (range < 1 to 12). Median time to maximum intensity was 10 minutes (range 0.2 to 180 minutes) with 49% of the pains reaching maximum intensity within 5 minutes. Median duration of the pains was 60 minutes (range 5 to 720 minutes). Patients could identify a precipitant for 60% of the pains and 89% of the precipitants were activity related. The onset of BTP could never be predicted for 49% of the pains and could only sometimes be predicted for 27% of the pains. These results suggest that BTP is common in noncancer patients with chronic neuropathic pain, often has a rapid onset (from baseline to peak intensity), has a relatively short duration, and is frequently difficult to predict, similar to BTP in cancer patients.
The prevalence and characteristics of breakthrough pain (BTP) were assessed in 121 back pain patients (59% women, 41% men) identified in a survey of chronic noncancer pain patients with controlled baseline pain (< T moderate intensity). Pain had been present for a median of 6 years (range 0.5-40 years). The underlying pain pathophysiology was felt to be nociceptive in 55%, neuropathic in 5%, and mixed in 40%. Medications being used included: any opioid in 82%, sustained-release opioids in 70%, methadone in 18%, short acting opioids in 78%, nonsteroidal antiinflammatory agents in 28%, antidepressants in 49%, and anticonvulsants in 33%. Phone interviews were used to characterized each patient's pain using a BTP pain assessment algorithm originally designed for cancer patients [1] . Seventy-three percent of these patients (88/121) reported temporary flares of severe or excruciating pain (i.e., BTP). Ninety-four different types of BTP were described by 88 patients. The median number of episodes per day was 2 (range < 1 to 12). Median time to maximum intensity was 10 minutes (range 1 to 120 minutes) with 48% of the pains reaching maximum intensity within 5 minutes. Median duration of the pains was 50 minutes (range 1 to 480 minutes). Patients could identify a precipitant for 77% of the pains and most (96%) of the precipitants were activity related. The onset of BTP could never be predicted for 46% of the pains and could only sometimes be predicted for 24% of the pains. These results suggest that noncancer patients with chronic back pain commonly experience BTP, which often has a rapid onset (from baseline to peak intensity), a relatively short duration, and is frequently difficult to predict. These findings are similar to what has been reported for BTP in cancer patients.
the relationship between relief of severe chronic pain with ziconotide and functional improvement.
reported "a lot" or "complete" satisfaction with treatment (P = 0.0027) and "very good" or "excellent" pain control (11.9% and 0.9%, respectively; P = 0.0004). The majority (84%) of AEs were mild to moderate in severity; discontinuation because of AEs was 5.4%, ziconotide; 4.6%, placebo. The most frequently reported ziconotide-related AEs were dizziness (34.8%), nausea (19.6%), and confusion (14.3%). Conclusions: Ziconotide efficacy was demonstrated in treatment-refractory patients showing significantly improved pain levels, patient satisfaction, and overall pain control. Ziconotide was well tolerated with primarily mild to moderate AEs and relatively low discontinuation rates. Outcome measures included treatment effect at 2 or 3 weeks on pain interference with sleep, general activity, mood, walking ability, normal work, relations with others, enjoyment of life, and on pain intensity as measured by the Brief Pain Inventory (BPI). In 286 geriatric patients (mean age, 76.9 years) with NP, 2 to 3 weeks of treatment with lidocaine patch 5% significantly reduced the degree to which pain interfered with sleep, and all other domains measured by question 9 of the BPI (P < 0.001). Lidocaine patch 5% also significantly reduced pain intensity and increased pain relief (P < 0.001). More than half (N = 144, 50.3%) experienced a ≥30% decrease in average daily pain from baseline. Treatment-related adverse events (AEs) were observed in 49 patients (17.1%), and were primarily mild-to-moderate in severity. The most commonly reported treatment-related AEs were dermal in nature (i.e., rash, N = 13 [4.5%]). In a geriatric population with NP, lidocaine patch 5% significantly reduced pain interference with sleep and other QOL domains; while providing a clinically meaningful reduction in pain intensity with low risk of systemic toxicity in an at-risk population.
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